Mycoplasma Infection

Mycoplasma infection, also known as mycoplasmosis, is a significant bacterial disease affecting multiple bird species caused by organisms belonging to the genus Mycoplasma. These unique bacteria lack cell walls, distinguishing them from typical bacteria and making them naturally resistant to antibiotics that target cell wall synthesis, such as penicillins and cephalosporins. Multiple Mycoplasma species affect birds, with Mycoplasma gallisepticum being particularly important in both poultry and wild finch populations, while other species including Mycoplasma synoviae, Mycoplasma meleagridis, and various species affect different bird groups. Mycoplasma infections occur in psittacines, passerines, poultry, raptors, and many other bird species, causing respiratory disease, conjunctivitis, joint infections, and reproductive problems depending on the specific Mycoplasma species involved.

The causes of Mycoplasma infection relate to direct transmission between birds and, significantly, vertical transmission from infected parents to offspring. These organisms spread through respiratory secretions, contaminated dust, and direct contact between birds. Infected birds may shed organisms even when appearing healthy, serving as reservoirs that perpetuate infection within flocks. Vertical transmission through infected eggs means chicks may hatch already carrying Mycoplasma organisms inherited from their parents. Stress, concurrent illness, poor environmental conditions, and inadequate nutrition increase both susceptibility to infection and severity of disease when infection occurs. Unlike many bacteria that survive well in the environment, Mycoplasma organisms are relatively fragile outside the host, though they can persist briefly on contaminated surfaces and in aerosols.

The impact of Mycoplasma infection on avian health varies considerably depending on the specific organism, the host species, and environmental factors. Respiratory involvement produces chronic respiratory disease with nasal discharge, swollen sinuses, breathing difficulties, and reduced activity. Eye involvement causes conjunctivitis that may progress to severe inflammation and potentially permanent damage. Joint infections produce lameness and swelling that can become chronic and debilitating. Reproductive involvement reduces fertility and hatch rates, with significant economic impact in breeding operations. Chronic infections may cause slow deterioration of health over months, while acute outbreaks in susceptible populations can produce rapid spread with significant morbidity and mortality.

Treatment of Mycoplasma infection requires antibiotics active against these cell wall-deficient organisms, primarily tetracyclines, macrolides, and fluoroquinolones. While treatment can reduce clinical signs and organism shedding, complete elimination of Mycoplasma is often difficult to achieve, and treated birds may remain carriers capable of transmitting infection. Avian veterinary care is essential for accurate diagnosis, appropriate antibiotic selection, and development of management strategies that address both individual bird treatment and flock or household disease control. Prevention through biosecurity measures and, in commercial poultry, vaccination programs represents the most effective approach to controlling Mycoplasma diseases.

Primary causes of Mycoplasma infection involve exposure to pathogenic organisms through horizontal transmission between birds or vertical transmission from parent to offspring. Horizontal spread occurs through respiratory secretions when birds are in close proximity, through contaminated dust and aerosols in shared airspaces, and through direct contact during social behaviors. Infected birds shed Mycoplasma organisms even during subclinical infection, making apparently healthy carriers important sources of transmission. Vertical transmission occurs when infected hens pass organisms to eggs during formation, resulting in infected embryos and chicks that hatch already carrying Mycoplasma. This vertical transmission perpetuates infection through generations and makes eradication from breeding populations particularly challenging.

Genetic and species-related factors influence susceptibility to Mycoplasma infection, with some species showing greater vulnerability than others. House finches in North America have demonstrated devastating susceptibility to Mycoplasma gallisepticum since the disease emerged in that population in the 1990s. Poultry species including chickens and turkeys have long histories of Mycoplasma diseases. Among psittacines, certain species may be more commonly affected, though comprehensive susceptibility data across psittacine species remains limited. Within species, individual genetic variation likely influences susceptibility and disease severity. Selective breeding in commercial poultry has developed lines with improved resistance to certain Mycoplasma species.

Environmental and husbandry factors significantly influence Mycoplasma transmission and disease severity. Overcrowding increases contact rates and stress, promoting both transmission and clinical disease development. Poor ventilation allows accumulation of contaminated aerosols in indoor spaces. Temperature extremes, particularly cold stress, increase respiratory disease susceptibility. Concurrent infections with other respiratory pathogens often occur alongside Mycoplasma and worsen disease severity. Inadequate nutrition compromises immune function and mucosal defenses. Breeding activities increase stress and contact opportunities while exposing offspring through vertical transmission. Mixed-species housing may introduce Mycoplasma organisms from carrier species to susceptible populations.

Risk factors for Mycoplasma infection development include exposure opportunities, immune status, and environmental stressors. Birds acquired from sources with unknown disease status or poor biosecurity practices face higher exposure risk. Young birds with developing immune systems may be more severely affected than immunocompetent adults. Immunosuppression from any cause, including concurrent viral infection, malnutrition, or stress, increases susceptibility. Environmental stressors including moves, introduction of new birds, breeding activities, and any disruption of normal routine may trigger clinical disease in subclinically infected carriers. Seasonal factors affect some Mycoplasma diseases, with increased incidence during certain times of year.

The mechanism of Mycoplasma infection development involves attachment to respiratory or other epithelial surfaces, colonization, immune evasion, and tissue damage. Mycoplasma organisms attach to host cells through specific adhesion proteins, establishing intimate contact with host cell membranes. Once attached, they multiply on epithelial surfaces and evade host immunity through several mechanisms including antigenic variation that helps them escape antibody recognition. Tissue damage results from direct effects of mycoplasmal metabolites on host cells, from the host inflammatory response to infection, and from secondary bacterial invasion when normal respiratory defenses are compromised. Chronic infection becomes established as organisms persist in protected sites despite immune responses, capable of recrudescing during periods of stress or immunosuppression.

Early warning signs of Mycoplasma infection are often subtle respiratory changes that may be attributed to minor irritation or environmental factors. Slight nasal discharge, initially clear and watery, represents one of the first noticeable signs. Mild sneezing or head shaking may occur as birds attempt to clear nasal passages. Subtle changes in respiratory sounds, including soft whistling or clicking, may be heard in quiet environments. Slight swelling around the eyes or sinuses may be apparent on close examination. Activity level may decrease slightly, with affected birds appearing less energetic than usual. These early signs frequently go unrecognized until disease progresses to more obvious clinical illness.

Common symptoms of established Mycoplasma infection vary depending on which body systems are primarily affected. Respiratory involvement produces nasal discharge that becomes increasingly thick and cloudy, swollen infraorbital sinuses causing facial distortion in severe cases, open-mouth breathing when nasal passages become obstructed, and abnormal respiratory sounds including rattling, clicking, or wheezing. Ocular involvement causes conjunctivitis with swollen, reddened eyelids, discharge ranging from watery to thick and purulent, crusting of eyelid margins, and potential vision impairment in severe cases. Joint involvement produces swelling, heat, and pain in affected joints, with obvious lameness and reluctance to move. Generalized symptoms include decreased appetite, weight loss, and reduced activity.

Behavioral changes accompany physical symptoms of Mycoplasma infection. Affected birds often become quieter and less interactive as illness progresses. Respiratory discomfort may cause increased yawning or gaping attempts to clear airways. Birds may rub their faces against perches or cage bars when sinus pressure develops. Appetite typically decreases as illness advances, though some birds maintain eating despite respiratory compromise. Sleep patterns may change, with increased rest periods and less active behavior. Social interactions may decrease, with affected birds withdrawing from flock mates. Vocalization often decreases, particularly in species that normally call or sing frequently.

Physical signs visible on examination reveal the characteristic manifestations of Mycoplasma infection. Nasal discharge may be visible around the nares, ranging from clear to cloudy, yellow, or green depending on secondary infection involvement. Sinus swelling produces visible facial distortion, particularly noticeable below and behind the eyes. Conjunctivitis causes visibly red, swollen eyes with discharge and potential crusting. Feathers around the face may be wet, matted, or stained from discharge. Birds may adopt mouth-breathing posture when nasal passages are obstructed. Joint swelling is visible and palpable when synovitis develops. Overall condition deteriorates with chronic infection, including weight loss and poor feather quality.

Symptom progression in Mycoplasma infection typically follows a pattern from mild to increasingly severe respiratory and systemic involvement. Early nasal symptoms advance to obvious sinusitis with facial swelling and thick discharge. Respiratory effort increases as lower respiratory involvement develops. Eye symptoms may progress from mild conjunctivitis to severe inflammation with potential corneal damage. General condition deteriorates with advancing disease, including progressive weight loss and weakness. Secondary bacterial infections commonly complicate Mycoplasma respiratory disease, worsening symptoms and potentially causing pneumonia. Chronic carriers may show intermittent symptoms that flare during stress periods then partially resolve, only to recur when conditions again favor disease expression.

Emergency symptoms requiring immediate veterinary attention include severe respiratory distress with open-mouth breathing and cyanosis, complete inability to eat or drink due to respiratory or ocular involvement, collapse or severe weakness, and eye changes suggesting potential corneal ulceration. While Mycoplasma infections typically progress gradually, severe cases can develop rapidly, particularly when secondary infections complicate the picture. Any bird showing significant respiratory compromise needs urgent evaluation. Birds with eye involvement require prompt attention to prevent permanent damage. Young birds and those with concurrent illness may deteriorate more rapidly than otherwise healthy adults, warranting lower thresholds for emergency care.

Initial examination for suspected Mycoplasma infection includes thorough history-taking about the bird's origin, exposure to other birds, duration and progression of symptoms, and any treatments already attempted. Physical examination focuses on respiratory system assessment including evaluation of nasal discharge character and quantity, palpation of sinuses for swelling, observation of breathing pattern and effort, and auscultation of airways and air sacs. Ocular examination assesses for conjunctivitis, discharge, and corneal involvement. Joint examination evaluates for swelling, heat, and pain indicating synovitis. The veterinarian assesses overall condition including body weight, hydration status, and systemic illness indicators. Environmental and management history helps assess exposure risk and identifies factors that may have triggered clinical disease.

Diagnostic tests for Mycoplasma infection employ several approaches depending on the clinical situation and available resources. PCR testing offers sensitive detection of Mycoplasma DNA from swabs of affected sites including the choana, conjunctiva, or synovial fluid. Culture of Mycoplasma is possible but requires specialized media and techniques not available in all laboratories, with prolonged incubation times. Serological testing detects antibodies against specific Mycoplasma species, indicating exposure though not necessarily current active infection. Cytology from discharge or aspirates may reveal inflammatory patterns suggestive of infection. Complete blood count may show changes consistent with chronic infection. Radiographs can assess respiratory involvement and detect changes in sinuses or air sacs.

Differential diagnosis for Mycoplasma infection must consider other conditions producing similar respiratory, ocular, or systemic signs. Chlamydiosis causes respiratory and ocular symptoms that overlap significantly with mycoplasmosis. Other bacterial respiratory infections including those caused by gram-negative organisms produce similar signs. Aspergillosis causes respiratory disease that may be confused with chronic mycoplasmal infection. Viral respiratory diseases in various species can produce comparable symptoms. Vitamin A deficiency causes ocular and respiratory epithelial changes that predispose to infection and may coexist with Mycoplasma. Environmental irritants including dust, smoke, and airborne chemicals can cause respiratory signs. The avian veterinarian uses clinical findings, history, and appropriate testing to differentiate among these possibilities.

Diagnosis confirmation relies on positive detection of Mycoplasma organisms through PCR, culture, or in some cases serological evidence combined with appropriate clinical presentation. Species identification helps determine prognosis and potential zoonotic concerns, though most avian Mycoplasma species do not affect humans. Response to appropriate antibiotic therapy supports the diagnosis, though clinical improvement alone does not confirm Mycoplasma versus other treatable causes. In flock situations, testing multiple birds may help establish the presence and distribution of infection. Repeat testing after treatment assesses whether organisms have been eliminated or whether carrier status persists. The veterinarian interprets diagnostic results in context of clinical findings and exposure history to reach diagnosis and guide management.

Emergency and immediate treatment for birds severely affected by Mycoplasma infection focuses on stabilization and symptomatic relief. Birds with respiratory distress benefit from oxygen supplementation and humidity support. Nasal and sinus lavage may help clear accumulated discharge and relieve obstruction. Nebulization delivers moisture and potentially antibiotics directly to respiratory tissues. Supportive care including fluids, nutritional support, and environmental warmth addresses general debilitation. Pain management may be appropriate for birds with joint involvement. Emergency eye treatment addresses acute conjunctivitis and protects corneal integrity. Antibiotic therapy typically begins immediately while awaiting diagnostic confirmation.

Medical management of Mycoplasma infection centers on antibiotic therapy using drugs active against these cell wall-deficient organisms. Tetracyclines, particularly doxycycline, have long been used effectively against avian Mycoplasma species. Macrolide antibiotics including tylosin, erythromycin, and azithromycin demonstrate activity against Mycoplasma. Fluoroquinolones such as enrofloxacin and marbofloxacin provide another effective option. Treatment duration typically extends for several weeks, with two to four weeks being common protocols, though longer treatment may be needed for chronic or severe infections. Response to treatment generally occurs within the first week, with continued improvement over the treatment course. However, treatment may not eliminate organisms entirely, and birds may remain carriers despite clinical resolution.

Surgical intervention occasionally becomes necessary for complications of Mycoplasma infection. Chronic sinusitis unresponsive to medical management may benefit from sinus drainage and flushing procedures. Severe infraorbital sinus distension may require surgical drainage combined with systemic and local antibiotic therapy. Joint infections rarely require surgical intervention but may need repeated aspiration for diagnosis and to relieve pressure. Surgical debridement is occasionally necessary for severe tissue damage. These procedures supplement rather than replace antibiotic therapy and require careful postoperative management.

Supportive care complements antibiotic treatment and significantly influences recovery from Mycoplasma infection. Environmental management maintains appropriate temperature and humidity to support respiratory function and recovery. Nutritional support ensures adequate intake during illness and recovery, with attention to vitamin A status given its importance for respiratory and ocular epithelial health. Nebulization with saline or medicated solutions helps maintain airway hydration and delivers topical treatment. Ocular medications including antibiotics and anti-inflammatory drops address conjunctivitis when present. Probiotics support gastrointestinal health during antibiotic therapy. Stress reduction through appropriate housing and minimal handling supports immune function.

Alternative and complementary treatments may support recovery alongside conventional therapy. Immune-supporting supplements may help birds mount more effective responses to infection. Herbal preparations with antimicrobial or immune-modulating properties have been explored, though evidence for efficacy against avian Mycoplasma remains limited. Environmental modifications that reduce stress support overall health and recovery. Appropriate nutrition optimization ensures birds have resources needed for recovery. These approaches should supplement rather than replace appropriate antibiotic therapy for Mycoplasma infection.

Treatment decisions for Mycoplasma infection consider individual bird factors, flock implications, and practical constraints. Birds in breeding programs require careful consideration of carrier potential and vertical transmission risk, as treated birds may remain capable of transmitting infection to offspring. Flock treatment may be necessary when multiple birds are exposed or affected. Cost of extended treatment and testing influences management decisions. The potential for antibiotic resistance development argues against inadequate treatment courses. Owner commitment to complete treatment protocols affects realistic planning. Long-term management strategies should address both acute treatment needs and ongoing carrier risk.

Recovery timeline from Mycoplasma infection varies based on disease severity, duration before treatment, and individual response to therapy. Mild infections treated promptly may show improvement within several days, with clinical resolution over one to two weeks. Moderate respiratory infections typically require several weeks to resolve, with gradual improvement in respiratory symptoms, discharge character, and overall condition. Severe chronic infections may require months of treatment and management, with incomplete resolution in some cases. Joint involvement often responds more slowly than respiratory disease, with healing potentially taking weeks to months. Eye involvement requires prompt treatment to prevent permanent damage, with recovery time depending on severity.

Post-treatment care focuses on completing antibiotic courses, monitoring for recurrence, and addressing carrier status concerns. Even when clinical signs resolve, continuing prescribed antibiotics for the full course helps reduce relapse risk. Follow-up examination assesses treatment response and detects residual disease. Repeat testing may be recommended to determine whether organisms have been eliminated or whether the bird remains a carrier. Environmental cleaning reduces recontamination risk. Attention to nutrition and stress reduction supports sustained recovery. Birds returning to group housing should be monitored for symptom recurrence and should not return to breeding programs without consideration of transmission risk.

Prognosis factors for Mycoplasma infection include promptness of treatment, severity of involvement, presence of complications, and individual immune competence. Birds treated early before chronic changes develop generally have excellent prognoses for clinical recovery. Severe respiratory involvement with secondary infection carries more guarded prognosis. Eye involvement prognosis depends on corneal integrity, with permanent damage possible if treatment is delayed. Joint involvement may result in chronic changes despite treatment. Young, otherwise healthy birds typically recover more completely than elderly or immunocompromised individuals. However, clinical recovery does not equal microbiological cure, and many treated birds remain carriers.

Long-term outlook for birds recovering from Mycoplasma infection must account for potential carrier status. Birds that remain carriers may experience recurrent symptoms during stress periods and can transmit infection to contact birds and offspring. In single-pet situations, carrier status may have limited practical significance if the bird remains clinically healthy. In multi-bird households, carrier birds pose ongoing transmission risk to susceptible flock mates. Breeding birds that are carriers can transmit infection vertically, perpetuating disease in offspring. Long-term management decisions should weigh individual bird welfare against flock health implications. Some owners choose to maintain recovered birds as permanent isolation cases rather than risk flock transmission.

Environmental prevention of Mycoplasma infection focuses on biosecurity measures that limit introduction and spread of organisms. Closed flock management, avoiding introduction of new birds, provides the most effective prevention but is not practical for many bird keepers. When new birds must be added, sourcing from Mycoplasma-tested negative flocks reduces introduction risk. Indoor housing eliminates exposure to wild birds that may carry Mycoplasma species. Air filtration and appropriate ventilation reduce airborne transmission within enclosed spaces. Regular cleaning and disinfection eliminate organisms from environmental surfaces, though Mycoplasma does not survive long outside hosts. Avoiding shared equipment between separate bird groups prevents mechanical transmission.

Quarantine protocols provide essential protection against Mycoplasma introduction when acquiring new birds. Extended quarantine periods of thirty to sixty days allow time for potentially infected birds to show clinical signs. Quarantine housing should maintain complete airspace separation from established birds. Veterinary examination and testing during quarantine can identify infected birds before introduction. Testing should target relevant Mycoplasma species based on the bird species involved. Negative tests provide some reassurance but do not guarantee absence of infection due to intermittent shedding and test sensitivity limitations. Birds with any respiratory or ocular symptoms during quarantine should not be introduced until fully evaluated and treated.

Dietary considerations support immune function that helps prevent Mycoplasma infection from causing clinical disease. Balanced nutrition appropriate for the species maintains immune competence. Vitamin A sufficiency is particularly important for respiratory and ocular epithelial health, as deficiency predisposes to infection and worsens disease when infection occurs. Quality protein supports immune function and tissue integrity. Fresh, clean food and water reduce stress on the immune system. Avoiding malnutrition and obesity both support optimal immune function. Supplements should be used judiciously under veterinary guidance.

Health maintenance through regular veterinary care enables early detection and management of Mycoplasma infection. Regular examinations allow detection of subtle respiratory or ocular changes before obvious disease develops. Health testing can include Mycoplasma screening for birds in breeding programs or multi-bird households. Prompt attention to any respiratory or ocular symptoms allows early treatment that limits disease severity and transmission. Understanding which Mycoplasma species affect specific bird types helps target appropriate testing. Vaccination is available for some Mycoplasma species in poultry but not for most companion bird species.

Early intervention when Mycoplasma infection is suspected limits disease progression and transmission. Any bird showing respiratory symptoms, ocular changes, or joint problems should receive prompt veterinary evaluation. Early treatment before chronic changes develop improves prognosis for complete resolution. Identifying affected birds and initiating treatment quickly limits shedding and transmission to contact birds. Separating symptomatic birds from healthy flock mates reduces spread while evaluation and treatment proceed. Testing contact birds helps identify subclinical carriers before they transmit infection further. Prompt response to disease outbreaks minimizes impact on bird populations.

Daily management of birds diagnosed with Mycoplasma infection requires consistent medication administration and ongoing symptom monitoring. Antibiotics should be given on schedule as prescribed, maintaining effective drug levels throughout treatment. Daily observation assesses respiratory status, eye condition, activity level, and appetite. Any worsening of symptoms should prompt veterinary consultation. Weight monitoring tracks overall condition and response to treatment. Environmental conditions should be optimized, with appropriate temperature, humidity, and air quality supporting respiratory health. Stress minimization helps immune function and reduces symptom severity.

Home environment modifications support recovery and reduce transmission risk. Separating infected birds from uninfected flock mates limits spread when possible. Improved ventilation reduces airborne organism concentration. Humidity maintenance supports respiratory function without creating conditions favoring organism survival on surfaces. Regular cleaning and disinfection of cage surfaces and accessories reduce environmental contamination. Food and water containers should be cleaned frequently to prevent contamination from respiratory discharge. Air filtration may benefit multi-bird households by reducing airborne transmission between separated groups.

Quality of life considerations remain important during Mycoplasma treatment and chronic management. Birds should continue receiving social interaction, mental stimulation, and appropriate environmental enrichment within the limits of their condition. Respiratory comfort measures including optimal humidity and clean air support wellbeing. Eye comfort requires keeping affected eyes clean and protecting them from irritation. Favorite foods may help maintain appetite during illness. Rest should be allowed while encouraging sufficient activity for physical condition maintenance. Chronic carriers that remain clinically healthy can enjoy good quality of life with appropriate management.

Monitoring and ongoing care responsibilities extend beyond acute treatment periods. Follow-up veterinary examinations assess treatment response and detect complications or recurrence. Repeat testing may determine carrier status and guide long-term management decisions. Ongoing attention to respiratory and ocular health catches early recurrence. Weight tracking provides objective measure of overall condition. Records of symptoms, treatments, and responses inform future management decisions. Understanding that stress may trigger recurrence in carriers guides long-term environmental and social management.

Caregiver support resources help owners manage the challenges of Mycoplasma infection in their birds. Understanding the nature of Mycoplasma infection, including potential carrier status and transmission concerns, helps owners make informed management decisions. Connection with avian veterinarians provides guidance for ongoing management questions. Online communities offer peer support, though medical decisions should be confirmed with veterinary professionals. Financial planning for potential long-term management helps reduce stress. When carrier status creates ongoing concerns for multi-bird households or breeding programs, honest assessment of options with veterinary guidance helps owners make appropriate decisions for their situations.

High-risk species for Mycoplasma infection include those with documented susceptibility and those commonly affected in clinical practice. House finches in North America have experienced devastating Mycoplasma gallisepticum outbreaks since the disease emerged in eastern populations in the 1990s, with continued spread and mortality. Other finch species including goldfinches, purple finches, and pine siskins are affected when exposed to M. gallisepticum. Poultry including chickens, turkeys, and game birds have long histories of Mycoplasma diseases causing significant economic losses. Raptors develop Mycoplasma infections, with some species showing particular susceptibility. Psittacines can be affected by various Mycoplasma species, with certain species appearing more commonly in clinical reports though comprehensive prevalence data remain limited.

Moderate-risk species include the broader population of birds that may encounter Mycoplasma through environmental exposure or contact with affected individuals. Canaries and other pet finches may be exposed through contact with wild finches or through introduction of infected birds. Budgerigars, cockatiels, and other commonly kept psittacines develop Mycoplasma infections with variable frequency. Pigeons and doves have their own Mycoplasma diseases. Waterfowl and other bird groups have associated Mycoplasma species. Mixed-species collections face complex exposure patterns as different birds may harbor different Mycoplasma species with varying host specificity.

Screening recommendations for Mycoplasma infection depend on the clinical situation, species involved, and management goals. Breeding programs should consider Mycoplasma testing to prevent vertical transmission and flock establishment of infection. New bird acquisitions warrant testing during quarantine, particularly when being introduced to established groups. Birds showing respiratory or ocular symptoms should be tested to confirm Mycoplasma involvement versus other causes. Testing contact birds during outbreaks helps identify subclinical carriers. The specific tests used should target Mycoplasma species relevant to the bird species being tested. Veterinary guidance helps select appropriate testing protocols for specific situations.

Commonly co-occurring conditions with Mycoplasma infection include other respiratory pathogens and secondary complications. Bacterial co-infections, particularly with gram-negative organisms, frequently complicate Mycoplasma respiratory disease, worsening symptoms and treatment challenges. Chlamydiosis may coexist with Mycoplasma infection, as both cause similar respiratory and ocular signs. Viral respiratory infections can occur simultaneously or predispose birds to Mycoplasma disease through immune suppression. Aspergillosis may develop as a secondary infection when Mycoplasma compromises respiratory defenses. Vitamin A deficiency both predisposes to Mycoplasma infection and commonly coexists with clinical disease. Stress-related conditions that trigger clinical disease in carriers may have their own manifestations.

Conditions with symptoms similar to Mycoplasma infection require differentiation for appropriate treatment. Chlamydiosis produces respiratory and ocular signs essentially indistinguishable from mycoplasmosis without laboratory testing. Other bacterial respiratory infections cause similar clinical presentations. Aspergillosis and other fungal infections cause respiratory disease that may be confused with Mycoplasma, particularly in chronic cases. Viral respiratory diseases produce overlapping symptoms in various species. Environmental irritant exposure can cause respiratory signs. Vitamin A deficiency causes ocular and respiratory changes. Foreign body in the nasal passages or sinuses can produce unilateral discharge. The avian veterinarian uses appropriate diagnostics to differentiate among these conditions.

Potential complications from Mycoplasma infection include both direct consequences and secondary problems. Chronic sinusitis may develop despite treatment, requiring ongoing management. Secondary bacterial infections complicate respiratory disease and may cause pneumonia. Corneal ulceration can result from severe conjunctivitis, potentially causing permanent vision impairment. Chronic joint involvement may cause permanent lameness. Carrier status persisting after clinical resolution poses ongoing transmission risks. Vertical transmission from carrier breeding birds perpetuates infection in offspring. Flock-wide establishment of Mycoplasma creates ongoing management challenges. These complications underscore the importance of prevention and early, aggressive treatment when infection occurs.